Advertisement

The anti-inflammatory actions of angiopoietin-1

  • Gavin Thurston
  • John S. Rudge
  • Ella Ioffe
  • Nicholas Papadopoulos
  • Christopher Daly
  • Srilatha Vuthoori
  • Thomas Daly
  • Stanley J. Wiegand
  • George D. Yancopoulos
Part of the Experientia Supplementum book series (EXS)

Keywords

Acute Lung Injury Human Umbilical Vein Endothelial Cell Evans Blue Perivascular Cell Plasma Leakage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87(7): 1161–1169PubMedCrossRefGoogle Scholar
  2. 2.
    Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A et al. (2003) Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10(1): 38–44PubMedCrossRefGoogle Scholar
  3. 3.
    Procopio WN, Pelavin PI, Lee WM, Yeilding NM (1999) Angiopoietin-1 and-2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J Biol Chem 274(42): 30196–30201PubMedCrossRefGoogle Scholar
  4. 4.
    Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, Haley KJ (2002) Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol-Lung Cell Mol Physiol 283(3): L585–595PubMedGoogle Scholar
  5. 5.
    Li JJ, Huang YQ, Basch R, Karpatkin S (2001) Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85(2): 204–206PubMedGoogle Scholar
  6. 6.
    Huang YQ, Li JJ, Karpatkin S (2000) Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 95(6): 1993–1999PubMedGoogle Scholar
  7. 7.
    Jones N, Dumont DJ (1998) The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 17(9): 1097–1108PubMedCrossRefGoogle Scholar
  8. 8.
    Jones N, Dumont DJ (2000) Tek/Tie2 signaling: new and old partners. Cancer Metastasis Rev 19(1-2): 13–17PubMedCrossRefGoogle Scholar
  9. 9.
    Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, Dumont DJ (1999) Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274(43): 30896–30905PubMedCrossRefGoogle Scholar
  10. 10.
    Fujikawa K, de Aos Scherpenseel I, Jain SK, Presman E, Christensen RA, Varticovski L (1999) Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res 253(2): 663–672PubMedCrossRefGoogle Scholar
  11. 11.
    Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, Altieri DC, Sessa WC (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275(13): 9102–9105PubMedCrossRefGoogle Scholar
  12. 12.
    Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, Hussain SN (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64(1): 135–147PubMedCrossRefGoogle Scholar
  13. 13.
    Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY (2000) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-Kinase/Akt signal transduction pathway. Circ Res 86(1): 24–29PubMedGoogle Scholar
  14. 14.
    Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322): 55–60PubMedCrossRefGoogle Scholar
  15. 15.
    Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA et al. (1999) Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96(5): 1904–1909PubMedCrossRefADSGoogle Scholar
  16. 16.
    Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Gene Dev 8(16): 1897–1909PubMedCrossRefGoogle Scholar
  17. 17.
    Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376(6535): 70–74PubMedCrossRefADSGoogle Scholar
  18. 18.
    Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87(7): 1171–1180PubMedCrossRefGoogle Scholar
  19. 19.
    Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD (1998) Increased vascularization in mice overexpressing angiopoietin-1. Science 282(5388): 468–471PubMedCrossRefADSGoogle Scholar
  20. 20.
    Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286(5449): 2511–2514PubMedCrossRefGoogle Scholar
  21. 21.
    Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111(1): 1–6PubMedCrossRefGoogle Scholar
  22. 22.
    Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17(3): 303–311PubMedCrossRefGoogle Scholar
  23. 23.
    Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102(1): 161–168PubMedCrossRefGoogle Scholar
  24. 24.
    Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6(4): 460–463PubMedCrossRefGoogle Scholar
  25. 25.
    Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA (2000) Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87(7): 603–607PubMedGoogle Scholar
  26. 26.
    Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A (2003) Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 139(2): 329–336PubMedCrossRefGoogle Scholar
  27. 27.
    Kim I, Moon SO, Park SK, Chae SW, Koh GY (2001) Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89(6): 77–479CrossRefGoogle Scholar
  28. 28.
    Kim I, Oh JL, Ryu YS, So JN, Sessa WC, Walsh K, Koh GY (2002) Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 16(1): 126–128PubMedGoogle Scholar
  29. 29.
    Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J et al. (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160(5): 1683–1693PubMedCrossRefGoogle Scholar
  30. 30.
    Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB (2003) Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107(9): 1308–1314PubMedCrossRefGoogle Scholar
  31. 31.
    Takahashi K, Ito Y, Morikawa M, Kobune M, Huang J, Tsukamoto M, Sasaki K, Nakamura K, Dehari H, Ikeda K et al. (2003) Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Mol Ther 8(4): 584–592PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson-Leger C, Imhof BA (2003) Forging the endothelium during inflammation: pushing at a half-open door? Cell Tissue Res 314(1): 93–105PubMedCrossRefGoogle Scholar
  33. 33.
    Majno G (1992) Maude Abbott Lecture — 1991. The capillary then and now: an overview of capillary pathology. Mod Pathol 5(1): 9–22PubMedGoogle Scholar
  34. 34.
    Majno G, Shea SM, Leventhal M (1969) Endothelial contraction induced by histamine-type mediators: an electron microscopic study. J Cell Biol 42(3): 647–672PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Gavin Thurston
    • 1
  • John S. Rudge
    • 1
  • Ella Ioffe
    • 1
  • Nicholas Papadopoulos
    • 1
  • Christopher Daly
    • 1
  • Srilatha Vuthoori
    • 1
  • Thomas Daly
    • 1
  • Stanley J. Wiegand
    • 1
  • George D. Yancopoulos
    • 1
  1. 1.Regeneron PharmaceuticalsTarrytownUSA

Personalised recommendations